Compare · BCAX vs NVO
BCAX vs NVO
Side-by-side comparison of Bicara Therapeutics Inc. (BCAX) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BCAX and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $222.81B, about 122.2x BCAX ($1.82B).
- BCAX has been more active in the news (5 items in the past 4 weeks vs 4 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 15 for BCAX).
- Company
- Bicara Therapeutics Inc.
- Novo Nordisk A/S
- Price
- $27.74+0.73%
- $50.31-2.25%
- Market cap
- $1.82B
- $222.81B
- 1M return
- -
- +15.47%
- 1Y return
- -
- -22.53%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2024
- News (4w)
- 5
- 4
- Recent ratings
- 15
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest BCAX
- Chief Executive Officer Mazumdar Claire exercised 10,000 shares at a strike of $3.79 and sold $284,198 worth of shares (10,000 units at $28.42) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Financial Officer Hyep Ivan exercised 12,500 shares at a strike of $3.79 and sold $807,672 worth of shares (28,000 units at $28.85) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 129,855 units (SEC Form 4)
- President and COO Cohlhepp Ryan exercised 18,750 shares at a strike of $3.79 and sold $833,129 worth of shares (28,750 units at $28.98) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 181,641 units (SEC Form 4)
- SEC Form 144 filed by Bicara Therapeutics Inc.
- Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- SEC Form 4 filed by Director Ra Capital Management, L.P.
- SEC Form 4 filed by Director Bowden Christopher
- SEC Form 4 filed by Director Haviland Kate
- SEC Form 4 filed by Director Mazumdar-Shaw Kiran
- SEC Form 4 filed by Director Robertson Scott M.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S